The primary goal is to develop easy accessible diagnostic tools for high risk subjects for colon cancer in different European populations to improve early CRC detection. These CRC screening technologies would be low cost, breakthrough and of high sensitivity and specificity.
CRC Group
Signature of the informed consent indicating that the subject accepts to participate in the study and to comply with the requirements and restrictions inherent in this study.
Subjects aged ≥18 years
Subject is willing to undergo FOBT test, colonoscopy, and tissue biopsy
For the CRC Group
Legal incapacity or limited legal capacity
Subject did not sign the Informed Consent form
Subject who, according to the investigator's assessment, presents with an unstable medical condition contraindicating the performance of the planned blood test, stool test or breath test
Firalis SA
Lead sponsor
University Medical Center Mainz
Collaborator